The role of anti-GD2 CH14.18/CHO monoclonal anti-body based immunotherapy within the HR-NBL1/SIOPEN trial. comparison of two treatment ERAS

被引：0

作者：

Ladenstein, Ruth ^{[1
,2
]}

Poetschger, Ulrike ^{[3
]}

Valteau-Couanet, Dominique ^{[4
]}

Luksch, Roberto ^{[5
]}

Castel, Victoria ^{[6
]}

Ash, Shifra ^{[7
]}

Laureys, Genevieve ^{[8
]}

Brock, Penelope ^{[9
]}

Michon, Jean Marie ^{[10
]}

Owens, Cormac ^{[11
]}

Trahair, Toby ^{[12
]}

Chan, Godfrey Chi Fung ^{[13
]}

Ruud, Ellen ^{[14
]}

Schroeder, Henrik ^{[15
]}

Popovic, Maja Beck ^{[16
]}

Schreier, Guenter ^{[17
]}

Loibner, Hans ^{[18
]}

Ambros, Peter ^{[19
]}

Holmes, Keith ^{[20
]}

Castellani, Maria Rita ^{[21
]}

Gaze, Mark N. ^{[22
]}

Garaventa, Alberto ^{[23
]}

Pearson, Andrew D. J. ^{[24
]}

Lode, Holger N. ^{[25
]}

机构：

[1] Med Univ, St Anna Childrens Hosp, Vienna, Austria

[2] Med Univ, CCRI, Vienna, Austria

[3] St Anna Kinderkrebsforsch, CCRI, Studies & Stat Integrated Res & Projects, Vienna, Austria

[4] Paris Sud Univ, Inst Cancerol, Gustave Roussy, Paris, France

[5] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[6] Hosp Univ & Politecn La Fe, Valencia, Spain

[7] Tel Aviv Univ, Sackler Fac Med, Schneider Childrens Med Ctr Israel, Petah Tiqwa, Israel

[8] Univ Hosp Ghent, Ghent, Belgium

[9] Great Ormond St Hosp Sick Children, London, England

[10] Inst Curie, Paris, France

[11] Our Ladys Childrens Hosp, Dublin, Ireland

[12] Sydney Childrens Hosp, Randwick, NSW, Australia

[13] Queen Mary Hosp, Hong Kong, Peoples R China

[14] Natl Hosp Norway, Oslo, Norway

[15] Univ Hosp Aarhus, Aarhus, Denmark

[16] Univ Hosp Lausanne, Lausanne, Switzerland

[17] AIT GmbH, Ctr Hlth & Bioresources, Graz, Austria

[18] Apeiron Biol AG, Vienna, Austria

[19] CCRI, Tumour Biol, Vienna, Austria

[20] St George Hosp, London, England

[21] Fdn IRCCS Ist Nazl Tumori Nucl Med, Milan, Italy

[22] Univ Coll London Hosp NHS Fdn Trust, Univ Coll London Hosp, Biomed Res Ctr, Natl Inst Hlth Res, London, England

[23] Ist Giannina Gaslini, Genoa, Italy

[24] Royal Marsden Hosp, Inst Canc Res, Sutton, Surrey, England

[25] Univ Med Greifswald, Greifswald, Germany

来源：

BONE MARROW TRANSPLANTATION | 2019年 / 54卷

关键词：

D O I：

暂无

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

O162

引用

页码：125 / 125

页数：1

共 17 条

[1] Immunotherapy with Anti-GD2 Antibody ch14.18/CHO±IL2 within the HR-NBL1/SIOPEN Trial Improves Outcome of High-Risk Neuroblastoma Patients Compared to Historical Controls
Ladenstein, R.
Poetschger, U.
Valteau-Couanet, D.
Gray, J.
Luksch, R.
Castel, V.
Ash, S.
Laureys, G.
Owens, C.
Trahair, T.
Chan, G. C. F.
Ruud, E.
Schroeder, H.
Beck-Popovic, M.
Loibner, H.
Schreier, G.
Ambros, P.
Sarnacki, S.
Boterberg, T.
Lode, H.
PEDIATRIC BLOOD & CANCER, 2018, 65 : S53 - S54
[2] Immunotherapy with anti-GD2 antibody ch14.18/CHO±IL2 within the HR-NBL1/SIOPEN trial to improve outcome of high-risk neuroblastoma patients compared to historical controls.
Ladenstein, Ruth Lydia
Poetschger, Ulrike
Couanet, Dominique Valteau
Gray, Juliet
Luksch, Roberto
Castel, Victoria
Ash, Shifra
Laureys, Genevieve
Owens, Cormac
Trahair, Toby
Chan, Godfrey Chi Fung
Ruud, Ellen
Schroeder, Henrik
Popovic, Maja Beck
Loibner, Hans
Schreier, Guenter
Ambros, Peter F.
Sarnacki, Sabine
Boterberg, Tom
Lode, Holger N.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[3] Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial
Ladenstein, Ruth
Poetschger, Ulrike
Valteau-Couanet, Dominique
Luksch, Roberto
Castel, Victoria
Yaniv, Isaac
Laureys, Genevieve
Brock, Penelope
Michon, Jean Marie
Owens, Cormac
Trahair, Toby
Chan, Godfrey Chi Fung
Ruud, Ellen
Schroeder, Henrik
Popovic, Maja Beck
Schreier, Guenter
Loibner, Hans
Ambros, Peter
Holmes, Keith
Castellani, Maria Rita
Gaze, Mark N.
Garaventa, Alberto
Pearson, Andrew D. J.
Lode, Holger N.
LANCET ONCOLOGY, 2018, 19 (12): : 1617 - 1629
[4] The influence of surgical excision on survival in high-risk neuroblastoma revisited after introduction of ch14.18/CHO immunotherapy in the HR-NBL1/SIOPEN trial.
Holmes, Keith
Poetschger, Ulrike
Sarnacki, Sabine
Monclair, Tom
Cecchetto, Giovanni
Chacon, Javier Gomez
Stenman, Jacob
Joseph, Jean-Marc
Luksch, Roberto
Castel, Victoria
Ash, Shifra
Papadakis, Vassilios
Malis, Josef
Balwierz, Walentyna
Owens, Cormac
Lode, Holger N.
Boterberg, Tom
Couanet, Dominique Valteau
Pearson, Andrew D. J.
Ladenstein, Ruth Lydia
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[5] Toxicity and outcome of anti-GD2 antibody ch14.18/CHO in front-line, high-risk patients with neuroblastoma: Final results of the phase III immunotherapy randomisation (HR-NBL1/SIOPEN trial).
Ladenstein, Ruth
Poetschger, Ulrike
Gray, Juliet
Valteau-Couanet, Dominique
Luksch, Roberto
Castel, Victoria
Yaniv, Isaac
Laureys, Genevieve
Elliott, Martin
Michon, Jean Marie
Owens, Cormac
Trahair, Toby
Chan, Godfrey Chi Fung
Ruud, Ellen
Schroeder, Henrik
Popovic, Maja Beck
Glogova, Evgenia
Schreier, Guenter
Loibner, Hans
Lode, Holger N.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[6] The Influence of Surgical Excision on Survival in High-Risk Neuroblastoma Revisited After Introduction of ch14.18/CHO Immunotherapy in the HR-NBL1/SIOPEN Trial
Ladenstein, R.
Poetschger, U.
Sarnacki, S.
Monclair, T.
Cecchetto, G.
Gomez-Chacon, J.
Stenman, J.
Joseph, J. M.
Luksch, R.
Castel, V.
Ash, S.
Papadakis, V.
Malis, J.
Balwierz, W.
Owens, C.
Lode, H.
Boterberg, T.
Valteau-Couanet, D.
Pearson, A. D.
Holmes, K.
PEDIATRIC BLOOD & CANCER, 2018, 65 : S36 - S37
[7] MYELOABLATIVE THERAPY (MAT) AND IMMUNOTHERAPY (IT) WITH CH14.18/CHO FOR HIGH RISK NEUROBLASTOMA: UPDATE AND NEWS OF RANDOMISED RESULTS FROM THE HR-NBL1/SIOPEN TRIAL
Ladenstein, R.
Poetschger, U.
Luksch, R.
Elliot, M.
Castel, V.
Yaniv, I.
Laureys, G.
Balwierz, W.
Lode, H. N.
Valteau-Couanet, D.
PEDIATRIC BLOOD & CANCER, 2014, 61 : S122 - S123
[8] PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO
Siebert, Nikolai
Zumpe, Maxi
Juettner, Madlen
Troschke-Meurer, Sascha
Lode, Holger N.
ONCOIMMUNOLOGY, 2017, 6 (10):
[9] Efficacy of ANTI-GD2 Antibody CH14.18/CHO and PD1/PD-L1 Checkpoint Blockade in Neuroblastoma
Lode, H.
Zumpe, M.
Juttner, M.
Troschke-Meurer, S.
Loibner, H.
Siebert, N.
PEDIATRIC BLOOD & CANCER, 2017, 64 : S42 - S42
[10] Effect of PD1/PD-L1 checkpoint blockade on efficacy of anti-GD2 antibody ch14.18/CHO in neuroblastoma.
Lode, Holger N.
Zumpe, Maxi
Juettner, Madlen
Troschke-Meurer, Sascha
Loibner, Hans
Siebert, Nikolai
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 →